Table 3.
Stratification analysis of the distribution of rs10499563 (-6331T>C) genotypes in lung cancer patients and controls
| Patients |
Controls |
Pa | OR (95 % CI)b |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TT, n(%) |
TC, n(%) |
CC, n(%) |
TT, n(%) |
TC, n (%) |
CC, n (%) |
TT | TC | CC | ||
| Discovery group | ||||||||||
| Age (years) | ||||||||||
| <60 | 212 (64.4) | 104 (31.6) | 13 (4.0) | 215 (61.6) | 111 (31.8) | 23 (6.6) | 0.295 | 1.00 | 0.99 (0.70–1.41) | 0.79 (0.54–1.14) |
| ≥60 | 185 (63.1) | 97 (33.1) | 11 (3.8) | 176 (66.4) | 77 (29.1) | 12 (4.5) | 0.559 | 1.00 | 1.12 (0.77–1.64) | 0.96 (0.62–1.49) |
| Gender | ||||||||||
| Female | 112 (68.7) | 46 (28.2) | 5 (3.1) | 144 (64.3) | 63 (28.1) | 17 (7.6) | 0.159 | 1.00 | 0.75 (0.52–1.08) | 0.62 (0.37–1.04) |
| Male | 285 (62.1) | 155 (33.8) | 19 (4.1) | 247 (63.3) | 125 (32.1) | 18 (4.6) | 0.839 | 1.00 | 1.13 (0.84–1.53) | 0.99 (0.70–1.40) |
| Smoking history | ||||||||||
| No | 154 (64.4) | 74 (31.0) | 11 (4.6) | 256 (62.9) | 127 (31.2) | 24 (5.9) | 0.769 | 1.00 | 0.97 (0.68–1.38) | 0.87 (0.60–1.26) |
| Yes | 243 (63.4) | 127 (33.2) | 13 (3.4) | 135 (65.2) | 61 (29.5) | 11 (5.3) | 0.395 | 1.00 | 1.15 (0.80–1.67) | 0.81 (0.54–1.23) |
| Histologyc | ||||||||||
| AC | 190 (64.8) | 92 (31.4) | 11 (3.8) | 391 (63.7) | 188 (30.6) | 35 (5.7) | 0.458 | 1.00 | 1.02 (0.75–1.39) | 0.81 (0.57–1.15) |
| SCC | 118 (64.1) | 61 (33.2) | 5 (2.7) | 0.246 | 1.00 | 1.10 (0.75–1.61) | 0.74 (0.45–1.22) | |||
| Others | 56 (59.6) | 33 (35.1) | 5 (5.3) | 0.682 | 1.00 | 1.25 (0.77–2.02) | 1.04 (0.63–1.72) | |||
| SCLC | 33 (64.7) | 15 (29.4) | 3 (5.9) | 0.984 | 1.00 | 0.95 (0.50–1.81) | 1.04 (0.56–1.95) | |||
| Validation group | ||||||||||
| Age (years) | ||||||||||
| <60 | 206 (63.4) | 99 (30.5) | 20 (6.1) | 233 (64.2) | 108 (29.7) | 22 (6.1) | 0.976 | 1.00 | 0.95 (0.67–1.34) | 1.05 (0.75–1.46) |
| ≥60 | 186 (64.1) | 84 (29.0) | 20 (6.9) | 161 (58.6) | 101 (36.7) | 13 (4.7) | 0.108 | 1.00 | 0.66 (0.45–0.96) | 1.11 (0.75–1.62) |
| Gender | ||||||||||
| Female | 104 (62.3) | 49 (29.3) | 14 (8.4) | 145 (62.8) | 71 (30.7) | 15 (6.5) | 0.763 | 1.00 | 1.01 (0.64–1.59) | 1.11 (0.75–1.64) |
| Male | 288 (64.3) | 134 (29.9) | 26 (5.8) | 249 (61.2) | 138 (33.9) | 20 (4.9) | 0.425 | 1.00 | 0.76 (0.56–1.02) | 1.10 (0.80–1.50) |
| Smoking history | ||||||||||
| No | 159 (65.4) | 67 (27.6) | 17 (7.0) | 263 (63.8) | 123 (29.9) | 26 (6.3) | 0.801 | 1.00 | 0.90 (0.63–1.29) | 1.04 (0.75–1.43) |
| Yes | 233 (62.6) | 116 (31.2) | 23 (6.2) | 131 (58.0) | 86 (38.0) | 9 (4.0) | 0.154 | 1.00 | 0.76 (0.53–1.08) | 1.21 (0.81–1.80) |
| Histologyc | ||||||||||
| AC | 195 (64.6) | 87 (28.8) | 20 (6.6) | 394 (61.7) | 209 (32.8) | 35 (5.5) | 0.422 | 1.00 | 0.79 (0.58–1.08) | 1.09 (0.81–1.46) |
| SCC | 107 (64.1) | 51 (30.5) | 9 (5.4) | 0.853 | 1.00 | 0.82 (0.56–1.21) | 1.02 (0.68–1.52) | |||
| Others | 64 (62.1) | 30 (29.1) | 9 (8.8) | 0.378 | 1.00 | 0.82 (0.51–1.32) | 1.42 (0.94–2.14) | |||
| SCLC | 26 (60.5) | 15 (34.9) | 2 (4.6) | 0.943 | 1.00 | 0.99 (0.51–1.94) | 0.97 (0.45–2.08) | |||
a
P values were determined using Chi-square test for distribution of genotypes
b
OR and 95 % CI were evaluated using logistic regression, adjusted for age, gender and smoking history
c
AC adenocarcinoma, SCC squamous cell carcinoma, Others including large cell carcinoma and adeno-squamous carcinoma, SCLC small-cell lung cancer